Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi 4Q Revenues up 2% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Sanofi 4Q Revenues up 2%

Dupixent and newly launched RSV vaccine Beyfortus help offset 74% decline in Aubagio sales due to generic competition.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi
4Q Revenues: €10.9 billion (+2%)
4Q Loss: €555 million (-118%)
FY Revenues: €43.1 billion (flat)
FY Earnings: €5.4 billion (-36%)
Comments: Specialty Care sales were up 13.7% in the quarter driven by Dupixent with sales of €2.99 billion, up 31%, and ALTUVIIIO launches, offsetting competition from generics of Aubagio in all key markets. Aubagio sales were down 74% to €121 million in the quarter. Myozyme sales were down 20% to €160 million. Nexviazyme sales were up 115% to €131 million in the quarter.
 
Vaccines sales increased 21% mainly due to the unprecedented uptake of RSV vaccine Beyfortus, reaching €410 million in the second quarter of its launch, offset by lower Influenza vaccines sales and COVID-19 vaccines. Influenza vaccines sales were down 4% to €741 million. 
Polio/Pertussis/Hib vaccines sales were up 3% to €434 million. Meningitis, Travel and endemic vaccines sales were up 10% to €242 million. Booster vaccines sales were down 1.4% to €139 million.
 
General Medicines declined 2% related to lower sales of Lantus and non-core asset divestment. Lantus sales were €277 million, down 24.9% in the quarter. Core assets sales increased 6.3% to €1.6 billion, mainly driven by the performance of Plavix, Toujeo, Rezurock, and Praluent partially offset by lower sales of Mozobil due to generic competition.

Biopharma business sales decreased 2.8% to €2.3 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters